GRCE · Grace Therapeutics, Inc.
$2.19
+0.05 (+2.34%)
At close · Aug 21
Market Cap
$46.28M
Shares
21.04M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.14
Open$2.19
Day$2.10–2.24
52W close$2.07–5.13
Avg vol 30d215K
Short int1.6M · 7.6% float · 5.7d
Short vol13%
Last earningsFeb 14, 2023
DataJul 2023–Aug 2026
Filing10-Q · Aug 13
Raw chart and full-history price indicators begin at the captured split on Jul 10, 2023; bars on opposite sides are not compared.
Up next
FQ2-27 quarter ends
~Sep 30, 2026
Est
filed Aug 13, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 16 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−32%
below
Price vs 50-day avg
−6%
below
RSI (14)
44
neutral
MACD trend
Positive
52-week position
2%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
−50%
trailing
YTD return
−38%
this year
Relative strength
−61%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$24.2K over 90 days · 0% sells
Short interest
Falling
7.56% of float · ▼ -2.6% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 2-yr range
Squeeze score
58
elevated · 0–100
Fundamentals
EPS growth
+41%
Y/Y
Balance sheet
$17.0M
net cash
Quant / Vol
risk profile
Volatility
70%
annualized · 1-yr
Max drawdown
−60%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−32%
Bearish
Price vs 50-day avg
−6%
Bearish
RSI (14)
44
Neutral
MACD trend
Positive
Bullish
52-week position
2%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-6% holders QoQ · +9 funds added
Insider flow
Accumulating
Net +$24.2K over 90 days · 0% sells
Short interest
Falling
7.56% of float · ▼ -2.6% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
33 holders — mid 2-yr range
Price context
position in its 52-week range
Range low $2
Now $2 · 2%
Range high $5
vs 200-day avg -32%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRCE
this stock
Grace Therapeutics, Inc.
|
$46.28M | -38.2% | -100.0% | — | 7.6% |
|
ONC
BeOne Medicines Ltd.
|
$557.05B | +21.5% | +22179.2% | 856.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$136.93B | +19.2% | +46.2% | 31.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$86.39B | +7.1% | +20.8% | 20.8 | 3.3% |
|
ARGX
Argenx SE
|
$64.56B | +23.4% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on Jul 10, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRCE | +3.4% | -8.9% | -50.1% | +2.9% | -38.2% |
| SPY | -2.0% | +3.3% | +11.2% | +2.1% | +11.8% |
| vs SPY | +5.3% | -12.3% | -61.3% | +0.8% | -50.0% |
Key facts
CIK
1444192
CUSIP
00439U104
13F (30d)
34 filings
34 filers
Visit website
Investor relations